 The 2020 COVID-19 pandemic has had a profound impact on the clinical research enterprises at the 60 Clinical and Translational Science Award, CTSA, hubs throughout the nation. There was simultaneously a need to expand research to obtain crucial data about disease prognosis and therapy. These imperatives resulted in major changes in the way research was conducted. This article was authored by Barry S. Coller, John B. Puse, Robert P. Kimberley and others.